Q4 2023, Salarius Pharmaceuticals reported a $0.9m ($0.22/share) net loss, lower than Q4 2022 ($6.4m, $2.
Salarius Pharmaceuticals reported a Q4 2023 net loss of $0.9m ($0.22/share), down from $6.4m ($2.83/share) in Q4 2022. The 2023 net loss was $12.5m ($3.84/share), compared to $31.6m ($14.88/share) in 2022, due to lower operating expenses from implemented cost-savings measures. Patient enrollment resumed for their Phase 1/2 clinical trial of seclidemstat with azacitidine for hematologic cancers.
March 22, 2024
3 Articles